COVID-19 Update

COVID-19 has imposed an unsettling situation upon our community and our business, but at Cleveland Diabetes Care and our affiliates, KRS Global Biotechnology and Complete Pharmacy Medical Solutions, we are committed to fighting back the best way we know how. By providing better medicine for better lives we will continue operations that include creation and distribution of life saving medications and testing kits to all reaches of our great nation.

KRS Global Blog

Glass Bits Force Recall of Daptomycin

Four lots of the intravenous antibiotic drug daptomycin (Cubicin) have been recalled because of glass particles found in some vials, the FDA and the drug’s manufacturer said.

No injuries have been reported, but the contamination could result in thromboembolism or granulomas, the FDA said.

The affected lot numbers are 950453F, 090203F, 201703F, and 201653F, with expiration dates ranging from Dec. 6, 2013, to Sept. 1, 2015. The lots were shipped from May 2011 to March of this year, according to a statement from manufacturer Cubist Pharmaceuticals posted on the FDA’s website.

Cubist said it was notifying customers by telephone and letter. All hospitals and clinics with inventories of daptomycin should check them for vials with the recalled lot numbers and contact the company if any are found. Cubist will arrange for return and replacement of recalled daptomycin vials.

The contamination appeared to originate with a third-party supplier, according to Cubist, which said it had “suspended all manufacturing with the supplier until corrective and preventative measures have been taken.”

Label directions for daptomycin specifically call for healthcare providers to check vials for visible particulates before administering the drug to patients, the firm noted. Vials containing particulates should not be used.